# EDGAR Filing Document

**Accession Number:** 0001761055
**File Stem:** 0001193125-26-064178
**Filing Date:** 2026-2
**Character Count:** 2457
**Document Hash:** 4fb20d2027a367ab0523b14d41de289b
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001193125-26-064178.hdr.sgml**: 20260223

**ACCESSION NUMBER**: 0001193125-26-064178

**CONFORMED SUBMISSION TYPE**: 497K

**PUBLIC DOCUMENT COUNT**: 1

**FILED AS OF DATE**: 20260223

**DATE AS OF CHANGE**: 20260223

**EFFECTIVENESS DATE**: 20260223

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** BlackRock ETF Trust
- **CENTRAL INDEX KEY:** 0001761055

**ORGANIZATION NAME:**
- **EIN:** 000000000
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 0731

**FILING VALUES:**
- **FORM TYPE:** 497K
- **SEC ACT:** 1933 Act
- **SEC FILE NUMBER:** 333-228832
- **FILM NUMBER:** 26665938

**BUSINESS ADDRESS:**
- **STREET 1:** 100 BELLEVUE PARKWAY
- **CITY:** WILMINGTON
- **STATE:** DE
- **ZIP:** 19809
- **BUSINESS PHONE:** 8004417762

**MAIL ADDRESS:**
- **STREET 1:** 100 BELLEVUE PARKWAY
- **CITY:** WILMINGTON
- **STATE:** DE
- **ZIP:** 19809

## Series and Classes Contracts Data

### iShares Health Innovation Active ETF (Series ID: S000069260)

| Class ID   | Class Name                           | Ticker Symbol   |
|:---|:---|:---|
| C000221226 | iShares Health Innovation Active ETF |  |

**BlackRock ETF Trust** 

iShares Health Innovation Active ETF

(the "Fund")

**Supplement dated February 23, 2026 to the Summary Prospectus and the** 

**Prospectus of the Fund, each dated November 28, 2025, as amended or supplemented to date** 

**Effective February 24, 2026, the following changes are made to the Fund's Summary Prospectus and Prospectus, as applicable:** 

**The section of the Summary Prospectus and the Prospectus entitled "Summary of Principal Risks" is amended to add the following:** 

***Focus Risk*.** Under normal circumstances, the Fund focuses its investments in the securities of a limited number of issuers. This may subject the Fund to greater issuer-specific risk and potential losses than a fund that invests in the securities of a greater number of issuers.

**The section of the Prospectus entitled "More Information About the Fund — A Further Discussion of Principal Risks" is amended to add the following:** 

**Focus Risk**. Under normal circumstances, the Fund focuses its investments in the securities of a limited number of issuers. This may subject the Fund to greater issuer-specific risk and potential losses than a fund that invests in the securities of a greater number of issuers.

**Shareholders should retain this Supplement for future reference.**

PR2-BMED-0226SUP